| pathology | Benefit (demonstrated or suggested) and harm | | | |
|---|
| acute coronary syndrome | All results are NS for efficacy | meta-analysis | | | Trial | control | p<0.05 | harm | NS |
|---|
| ERASE-MI, 2009 | vs placebo | | | major bleeding NaN [NaN; NaN] non fatla stroke ∞ [NaN; ∞] non fatal MI NaN [NaN; NaN] |
| Trial | Treatments | Patients | Method |
|---|
| ERASE-MI, 2009 | elinogrel 10, 20, 40, or 60 mg as a single intravenous bolus (n=34) vs. placebo (n=36) 5 arms: 4 doses of elinogrel or placebo before the start of the diagnostic angiogram preceding primary PCI | STEMI patients | double blind Parallel groups Sample size: 34/36 Primary endpoint: TIMI and ST resolution FU duration: 30-37 days phase IIb (dose-escalation study) |
|
| acute myocardial infarction | All results are NS for efficacy | meta-analysis | | | Trial | control | p<0.05 | harm | NS |
|---|
| ERASE-MI, 2009 | vs placebo | | | major bleeding NaN [NaN; NaN] non fatla stroke ∞ [NaN; ∞] non fatal MI NaN [NaN; NaN] |
| Trial | Treatments | Patients | Method |
|---|
| ERASE-MI, 2009 | elinogrel 10, 20, 40, or 60 mg as a single intravenous bolus (n=34) vs. placebo (n=36) 5 arms: 4 doses of elinogrel or placebo before the start of the diagnostic angiogram preceding primary PCI | STEMI patients | double blind Parallel groups Sample size: 34/36 Primary endpoint: TIMI and ST resolution FU duration: 30-37 days phase IIb (dose-escalation study) |
|
| percutaneous coronary intervention | All results are NS for efficacy | meta-analysis | | | Trial | control | p<0.05 | harm | NS |
|---|
| INNOVATE PCI | vs clopidogrel | | | |
| Trial | Treatments | Patients | Method |
|---|
| INNOVATE PCI | (n=-9) vs. (n=-9) | | Sample size: -9/-9 Primary endpoint: FU duration: |
|
